LABU's Holdings Imply 58% Gain Potential
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 10 2025
0mins
Source: NASDAQ.COM
ETF Analysis: The Direxion Daily S&P Biotech Bull 3X Shares ETF (LABU) has an implied analyst target price of $105.45, indicating a potential upside of 57.51% from its current trading price of $66.95.
Stock Performance Insights: Notable underlying holdings such as IDEAYA Biosciences, Denali Therapeutics, and Replimune Group show significant upside potential based on analysts' target prices, raising questions about the validity and optimism of these projections.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DNLI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DNLI
Wall Street analysts forecast DNLI stock price to rise
10 Analyst Rating
10 Buy
0 Hold
0 Sell
Strong Buy
Current: 19.300
Low
25.00
Averages
32.78
High
40.00
Current: 19.300
Low
25.00
Averages
32.78
High
40.00
About DNLI
Denali Therapeutics Inc. is a biopharmaceutical company establishing a new class of biotherapeutics designed to cross the blood-brain barrier using its TransportVehicle platform. It is focused on building a portfolio of therapeutic candidates by investing in its TV franchises, i.e., Enzyme TV (ETV), Oligonucleotide TV (OTV), and Antibody TV (ATV), to advance programs for rare diseases, such as lysosomal storage diseases, and common diseases, such as Alzheimer's disease and Parkinson's disease. Its most advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (Hunter syndrome). TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for mucopolysaccharidosis IIIA (Sanfilippo syndrome type A), DNL593 (PTV:PGRN) for frontotemporal dementia-granulin, DNL628 (OTV:MAPT) for Alzheimer’s disease, and DNL952 (ETV:GAA) for Pompe disease. It is also pursuing opportunities in other disease areas including oncology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
US Stocks Close Higher as Market Sentiment Improves
- Market Recovery: The S&P 500 rose by 0.37% and the Nasdaq 100 by 0.42%, with the Dow Jones Industrial Average hitting an all-time high, reflecting optimism about a potential US-Iran peace deal that could boost investor confidence.
- Consumer Sentiment Decline: The University of Michigan's consumer sentiment index was revised down to a record low of 44.8, below the expected 48.2, indicating growing concerns among consumers about the economic outlook, which may impact future spending.
- Rising Inflation Expectations: The 1-year inflation expectations for May were revised upward to 4.8%, exceeding the expected 4.6%, potentially prompting the Federal Reserve to consider interest rate hikes in upcoming meetings, which could pressure the stock market.
- Tech Stocks Lead Gains: Workday's stock surged over 5% after reporting Q1 adjusted EPS of $2.66, surpassing expectations, highlighting strong performance in the software sector and potentially attracting more investor interest in tech stocks.
See More
US Stocks Rise, Nasdaq Hits Weekly High
- Strong Market Performance: The S&P 500 rose by 0.50% and the Nasdaq 100 by 0.73%, with the Dow Jones Industrial Average hitting an all-time high, reflecting optimism about a potential US-Iran peace deal that could boost investor confidence.
- Decline in Consumer Confidence: The University of Michigan's consumer sentiment index was revised down to 44.8, a record low, below the expected 48.2, indicating growing consumer concerns about the economic outlook, which may negatively impact future spending.
- Rising Inflation Expectations: The 1-year inflation expectations for May were revised up to 4.8%, a 9-month high, exceeding the expected 4.6%, which could prompt the Fed to consider interest rate hikes at the upcoming meeting, affecting market liquidity.
- Chip Stocks Lead Gains: Qualcomm's stock surged over 12%, leading the Nasdaq 100, demonstrating ongoing market enthusiasm for semiconductor and AI infrastructure, which may yield higher returns for related companies.
See More
US Stocks Rise as Market Optimism Grows
- Strong Market Performance: The S&P 500 rose by 0.54%, the Nasdaq 100 increased by 0.53%, and the Dow Jones Industrial Average reached an all-time high, reflecting market optimism regarding a potential peace deal between the US and Iran, which could boost investor confidence.
- Software Stocks Lead Gains: Workday's stock surged over 8% after reporting Q1 adjusted EPS of $2.66, exceeding the consensus of $2.51, and forecasting Q2 subscription revenue of $2.46 billion, further enhancing confidence in the software sector.
- Oil Price Volatility Affects Markets: Crude oil prices dipped slightly as Qatar coordinated with the US to send a negotiating team to Tehran, raising concerns about future supply; the IEA warned that global oil inventories will remain tight, potentially impacting overall economic growth.
- International Markets Rebound: The Euro Stoxx 50 climbed 1.23%, China's Shanghai Composite rose 0.87%, and Japan's Nikkei increased by 2.68%, indicating a global market optimism that may provide support for the US market.
See More
Biogen and Denali Halt Development of Parkinson's Drug BIIB122
- Trial Setback: Biogen (BIIB) and Denali (DNLI) announced the discontinuation of BIIB122 after their Phase 2b LUMA study for early-stage Parkinson's disease failed to meet primary and secondary endpoints, marking a significant setback in their drug development efforts.
- Mechanism Exploration: BIIB122 was designed to inhibit the LRRK2 mutation associated with Parkinson's disease; despite the disappointing results, Denali's medical chief, Peter Chin, emphasized the need for further exploration of LRRK2 as a potential therapeutic target, indicating future research directions.
- Continued Research: Denali will proceed with its Phase 2a BEACON study for BIIB122 in LRRK2-associated Parkinson's disease, which is expected to generate data in H1 2027, potentially providing new insights into treatment options in this area.
- Market Reaction: Following the announcement, shares of Biogen and Denali fell in premarket trading on Friday, reflecting investor concerns about the companies' prospects in the neurodegenerative disease space, which may impact future funding and R&D investments.
See More
Biogen and Denali Halt Development of Parkinson's Drug BIIB122
- Clinical Trial Results: Biogen and Denali's LUMA study revealed that BIIB122 did not slow disease progression compared to placebo, with the primary endpoint failing to meet expectations, indicating significant shortcomings in the drug's therapeutic efficacy.
- Biomarker Analysis: Although exploratory biomarker data confirmed over 90% peripheral LRRK2 kinase inhibition, cerebrospinal fluid analysis showed only a 30% reduction in phosphorylated Rab10, failing to substantiate the drug's clinical effectiveness.
- Safety Assessment: BIIB122 maintained stable drug levels in blood and cerebrospinal fluid, and was generally well tolerated, with safety data indicating no severe adverse reactions during short-term use.
- Future Plan Adjustments: Based on the trial results, Biogen and Denali decided to discontinue further development of BIIB122 in idiopathic Parkinson's disease, while Denali will independently continue with the Phase 2a BEACON study targeting carriers of pathogenic LRRK2 variants.
See More
Biogen and Denali Halt Parkinson's Drug Development
- Trial Failure: Biogen and Denali announced that their mid-stage LUMA study of the experimental Parkinson's drug BIIB122 failed to meet its primary and secondary endpoints, resulting in a 1% drop in Biogen's stock and a 7% decline in Denali's stock during after-hours trading.
- Safety Profile: Despite the trial's failure to demonstrate improvement in motor and daily living symptoms, the companies reported that the drug was generally well tolerated with an acceptable safety profile and showed strong target engagement in the body.
- Future Research Plans: Biogen and Denali will cease further development of BIIB122 for the broader idiopathic form of Parkinson's, but Denali will continue its BEACON study focused on a smaller group of patients with a specific genetic mutation, with results expected in the first half of 2027.
- Market Sentiment: Retail sentiment on Stocktwits for BIIB and DNLI stocks was bearish at the time of writing, accompanied by high message volume, even though BIIB shares have gained 49% and DNLI shares have increased by 41% over the past 12 months.
See More
US Stocks Close Higher as Market Sentiment Improves
- Market Recovery: The S&P 500 rose by 0.37% and the Nasdaq 100 by 0.42%, with the Dow Jones Industrial Average hitting an all-time high, reflecting optimism about a potential US-Iran peace deal that could boost investor confidence.
- Consumer Sentiment Decline: The University of Michigan's consumer sentiment index was revised down to a record low of 44.8, below the expected 48.2, indicating growing concerns among consumers about the economic outlook, which may impact future spending.
- Rising Inflation Expectations: The 1-year inflation expectations for May were revised upward to 4.8%, exceeding the expected 4.6%, potentially prompting the Federal Reserve to consider interest rate hikes in upcoming meetings, which could pressure the stock market.
- Tech Stocks Lead Gains: Workday's stock surged over 5% after reporting Q1 adjusted EPS of $2.66, surpassing expectations, highlighting strong performance in the software sector and potentially attracting more investor interest in tech stocks.
See More
US Stocks Rise, Nasdaq Hits Weekly High
- Strong Market Performance: The S&P 500 rose by 0.50% and the Nasdaq 100 by 0.73%, with the Dow Jones Industrial Average hitting an all-time high, reflecting optimism about a potential US-Iran peace deal that could boost investor confidence.
- Decline in Consumer Confidence: The University of Michigan's consumer sentiment index was revised down to 44.8, a record low, below the expected 48.2, indicating growing consumer concerns about the economic outlook, which may negatively impact future spending.
- Rising Inflation Expectations: The 1-year inflation expectations for May were revised up to 4.8%, a 9-month high, exceeding the expected 4.6%, which could prompt the Fed to consider interest rate hikes at the upcoming meeting, affecting market liquidity.
- Chip Stocks Lead Gains: Qualcomm's stock surged over 12%, leading the Nasdaq 100, demonstrating ongoing market enthusiasm for semiconductor and AI infrastructure, which may yield higher returns for related companies.
See More
US Stocks Rise as Market Optimism Grows
- Strong Market Performance: The S&P 500 rose by 0.54%, the Nasdaq 100 increased by 0.53%, and the Dow Jones Industrial Average reached an all-time high, reflecting market optimism regarding a potential peace deal between the US and Iran, which could boost investor confidence.
- Software Stocks Lead Gains: Workday's stock surged over 8% after reporting Q1 adjusted EPS of $2.66, exceeding the consensus of $2.51, and forecasting Q2 subscription revenue of $2.46 billion, further enhancing confidence in the software sector.
- Oil Price Volatility Affects Markets: Crude oil prices dipped slightly as Qatar coordinated with the US to send a negotiating team to Tehran, raising concerns about future supply; the IEA warned that global oil inventories will remain tight, potentially impacting overall economic growth.
- International Markets Rebound: The Euro Stoxx 50 climbed 1.23%, China's Shanghai Composite rose 0.87%, and Japan's Nikkei increased by 2.68%, indicating a global market optimism that may provide support for the US market.
See More
Biogen and Denali Halt Development of Parkinson's Drug BIIB122
- Trial Setback: Biogen (BIIB) and Denali (DNLI) announced the discontinuation of BIIB122 after their Phase 2b LUMA study for early-stage Parkinson's disease failed to meet primary and secondary endpoints, marking a significant setback in their drug development efforts.
- Mechanism Exploration: BIIB122 was designed to inhibit the LRRK2 mutation associated with Parkinson's disease; despite the disappointing results, Denali's medical chief, Peter Chin, emphasized the need for further exploration of LRRK2 as a potential therapeutic target, indicating future research directions.
- Continued Research: Denali will proceed with its Phase 2a BEACON study for BIIB122 in LRRK2-associated Parkinson's disease, which is expected to generate data in H1 2027, potentially providing new insights into treatment options in this area.
- Market Reaction: Following the announcement, shares of Biogen and Denali fell in premarket trading on Friday, reflecting investor concerns about the companies' prospects in the neurodegenerative disease space, which may impact future funding and R&D investments.
See More
Biogen and Denali Halt Development of Parkinson's Drug BIIB122
- Clinical Trial Results: Biogen and Denali's LUMA study revealed that BIIB122 did not slow disease progression compared to placebo, with the primary endpoint failing to meet expectations, indicating significant shortcomings in the drug's therapeutic efficacy.
- Biomarker Analysis: Although exploratory biomarker data confirmed over 90% peripheral LRRK2 kinase inhibition, cerebrospinal fluid analysis showed only a 30% reduction in phosphorylated Rab10, failing to substantiate the drug's clinical effectiveness.
- Safety Assessment: BIIB122 maintained stable drug levels in blood and cerebrospinal fluid, and was generally well tolerated, with safety data indicating no severe adverse reactions during short-term use.
- Future Plan Adjustments: Based on the trial results, Biogen and Denali decided to discontinue further development of BIIB122 in idiopathic Parkinson's disease, while Denali will independently continue with the Phase 2a BEACON study targeting carriers of pathogenic LRRK2 variants.
See More
Biogen and Denali Halt Parkinson's Drug Development
- Trial Failure: Biogen and Denali announced that their mid-stage LUMA study of the experimental Parkinson's drug BIIB122 failed to meet its primary and secondary endpoints, resulting in a 1% drop in Biogen's stock and a 7% decline in Denali's stock during after-hours trading.
- Safety Profile: Despite the trial's failure to demonstrate improvement in motor and daily living symptoms, the companies reported that the drug was generally well tolerated with an acceptable safety profile and showed strong target engagement in the body.
- Future Research Plans: Biogen and Denali will cease further development of BIIB122 for the broader idiopathic form of Parkinson's, but Denali will continue its BEACON study focused on a smaller group of patients with a specific genetic mutation, with results expected in the first half of 2027.
- Market Sentiment: Retail sentiment on Stocktwits for BIIB and DNLI stocks was bearish at the time of writing, accompanied by high message volume, even though BIIB shares have gained 49% and DNLI shares have increased by 41% over the past 12 months.
See More
